Analyst firms · H.C. Wainwright · DRNA

H.C. Wainwright DRNA price target and rating history

Dicerna Pharmaceuticals, Inc. (DRNA) · Health Care

H.C. Wainwright rates Dicerna Pharmaceuticals, Inc. (DRNA) Neutral with a $38.25 price target, as of its latest action on Nov 18, 2021. It has published 4 rating actions on DRNA since June 2021, including 0 upgrades and 1 downgrade.

Current rating
Neutral
Price target
$38.25
Median target, all firms
Too few
Actions on DRNA
4

H.C. Wainwright price target on DRNA

$42$37$3220222023202420252026
H.C. Wainwright price target on DRNA, each point a stated target, June 2021 to November 2021.

Every H.C. Wainwright rating on DRNA

Questions about H.C. Wainwright and DRNA

What is H.C. Wainwright's price target for DRNA?
H.C. Wainwright's latest stated price target for Dicerna Pharmaceuticals, Inc. (DRNA) is $38.25, from its action on Nov 18, 2021.
What is H.C. Wainwright's rating on DRNA?
H.C. Wainwright rates DRNA Neutral, a neutral rating, as of Nov 18, 2021.
When did H.C. Wainwright last change its view on DRNA?
On Nov 18, 2021, H.C. Wainwright downgrades to Neutral from Buy, price target $32 to $38.25.

All H.C. Wainwright ratingsDRNA news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.